Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science.
about
Innovative clinical trial design for pediatric therapeuticsDevelopment of biomarkers to optimize pediatric patient management: what makes children different?Strategic biomarkers for drug development in treating rare diseases and diseases in neonates and infantsClinical pharmacology in neonates: small size, huge variabilityClinical pharmacological studies in children: From exploratory towards confirmation driven methodology.Developmental pharmacogenetics in pediatric rheumatology: utilizing a new paradigm to effectively treat patients with juvenile idiopathic arthritis with methotrexate.Identifying genomic and developmental causes of adverse drug reactions in children.Ethical considerations for pharmacogenomic testing in pediatric clinical care and research.Towards early inclusion of children in tuberculosis drugs trials: a consensus statementDetection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomicsObservational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis.Characteristics of successful recruitment in prospective pediatric pharmacogenetic studiesPersonalised medicine in paediatrics: individualising treatment in children with rare neurological diseases.Conference scene: pediatric pharmacogenomics and personalized medicine.Clinical pharmacology in neonates and young infants: the benefit of a population-tailored approach.Perinatal pharmacologyEthical issues in pediatric pharmacogenomics.Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation.Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children.Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs.The status of paediatric medicines initiatives around the world--What has happened and what has not?Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children.Tailored tools to improve pharmacotherapy in infants.Pharmacogenomic biomarker information in FDA-approved paediatric drug labels.Personalised dosing of medicines for children.Exposure Matching for Extrapolation of Efficacy in Pediatric Drug Development.Enrolling Adolescents in Disease/Target-Appropriate Adult Oncology Clinical Trials of Investigational Agents.Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients.Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates.Developmental pharmacology.Pharmacokinetic studies in children: recommendations for practice and research.Product Substitution as a Way Forward in Avoiding Potentially Harmful Excipients in Neonates.
P2860
Q24635308-AFB9D1C5-D02F-4DD0-8128-AE421D7AFBCFQ26822946-A1FB07F2-D5F1-41D8-AADA-C8B9B0A1594FQ27024346-F226662D-D53B-44D3-902B-B1C051DF24A0Q33950874-AC33ADD1-F040-46B0-95D4-5E79E2C7D862Q34093287-F295AFF6-B04D-4491-872E-8AFA1F34B866Q34219644-E6BD0E5C-598A-4DC6-8410-0C07A49EB4B5Q34603032-41A0269C-D135-4917-A921-BECFFB47B7AEQ35187838-550BD637-DD42-41B0-BA98-03DE52E960A4Q35752740-EAE1E645-52D9-48F9-8473-1AB11514803DQ35800807-8069B5B1-DD99-44DF-B091-5FF85324C4DBQ35846147-F3243ED8-85FF-4236-BFC9-BDDE52B86F0AQ35871392-DD09F4F5-79F0-4193-8BB3-1E1F4E9BA728Q36117928-538065D9-3A79-4089-B999-BA0D391AC4E6Q36176606-0378F520-935D-4421-9485-874FA466418FQ36452352-B6A06D72-9589-4332-BDE0-C45B57260894Q36452361-EEA92875-5076-4FBA-A90B-75009ACD51F6Q37178365-4C4F6A12-3FD4-4275-ACE4-69C6AC48CBB1Q37358921-48FB7A46-BF38-4731-B73D-6E2F64F5EB97Q37872786-ABF28CD2-1722-4BBB-8E29-8D02CA311F1BQ37892531-F5D820CE-7BA5-469A-92AB-CF7D25AE9DA3Q37898039-1BE6008A-89CF-4B92-A014-4E2F2EDD7ABAQ37994062-307E39AD-AB9E-45E9-A3FF-EFEFCCCA537AQ38049379-2850C697-2254-4E97-91F6-33DF55A18607Q38222870-8302D6DD-B814-4C80-A162-9CD3F9A76862Q38263127-2CE5FF6E-128A-4E51-9E57-E5B6246A42E7Q38749764-01249B7C-39BD-48D6-830E-2740D787B941Q38797102-E27705B7-F7D1-4266-AB8D-FB70DF5992F6Q38990759-239877CC-3720-4AAC-B8AC-30BAD0E79E8AQ40181637-7DA9C001-AC28-4C02-B620-329E274A4FF6Q47428031-F2D14575-4C3D-4DE8-AB67-B15F93174B36Q51897014-86B02626-19CA-4AA0-8F0D-DF41B30B48DBQ52576551-45257EA1-7F1C-49F5-851C-858F6B2CFC4FQ53616631-C5521445-F7CB-438D-B8F8-51B0CEF8819D
P2860
Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Understanding the relative rol ...... opment and regulatory science.
@en
Understanding the relative rol ...... opment and regulatory science.
@nl
type
label
Understanding the relative rol ...... opment and regulatory science.
@en
Understanding the relative rol ...... opment and regulatory science.
@nl
prefLabel
Understanding the relative rol ...... opment and regulatory science.
@en
Understanding the relative rol ...... opment and regulatory science.
@nl
P2093
P2860
P356
P1476
Understanding the relative rol ...... opment and regulatory science.
@en
P2093
Gregory L Kearns
J Steven Leeder
John van den Anker
Stephen P Spielberg
P2860
P304
P356
10.1177/0091270009360533
P577
2010-02-11T00:00:00Z